These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1076 related items for PubMed ID: 8203723

  • 21. Exploration of mucosal immunity in humans: relevance to vaccine development.
    Czerkinsky C, Holmgren J.
    Cell Mol Biol (Noisy-le-grand); 1994; 40 Suppl 1():37-44. PubMed ID: 7950860
    [Abstract] [Full Text] [Related]

  • 22. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
    Roland KL, Cloninger C, Kochi SK, Thomas LJ, Tinge SA, Rouskey C, Killeen KP.
    Vaccine; 2007 Dec 12; 25(51):8574-84. PubMed ID: 18045752
    [Abstract] [Full Text] [Related]

  • 23. Cholera toxin and cholera toxin B subunit induce IgA switching through the action of TGF-beta 1.
    Kim PH, Eckmann L, Lee WJ, Han W, Kagnoff MF.
    J Immunol; 1998 Feb 01; 160(3):1198-203. PubMed ID: 9570534
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI, Kurata T.
    Jpn J Infect Dis; 2000 Jun 01; 53(3):98-106. PubMed ID: 10957706
    [Abstract] [Full Text] [Related]

  • 26. New perspectives in vaccine development: mucosal immunity to infections.
    McGhee JR, Kiyono H.
    Infect Agents Dis; 1993 Apr 01; 2(2):55-73. PubMed ID: 8162356
    [Abstract] [Full Text] [Related]

  • 27. Cholera toxin B subunit modulation of mucosal vaccines for infectious and autoimmune diseases.
    Langridge W, Dénes B, Fodor I.
    Curr Opin Investig Drugs; 2010 Aug 01; 11(8):919-28. PubMed ID: 20721834
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Strong mucosal adjuvanticity of cholera toxin within lipid particles of a new multiple emulsion delivery system for oral immunization.
    Tomasi M, Dertzbaugh MT, Hearn T, Hunter RL, Elson CO.
    Eur J Immunol; 1997 Oct 01; 27(10):2720-5. PubMed ID: 9368632
    [Abstract] [Full Text] [Related]

  • 30. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization.
    Vajdy M, Lycke NY.
    Immunology; 1992 Mar 01; 75(3):488-92. PubMed ID: 1572696
    [Abstract] [Full Text] [Related]

  • 31. Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells.
    George Chandy A, Hultkrantz S, Raghavan S, Czerkinsky C, Lebens M, Telemo E, Holmgren J.
    Immunology; 2006 Jul 01; 118(3):311-20. PubMed ID: 16827892
    [Abstract] [Full Text] [Related]

  • 32. Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant.
    Rask C, Fredriksson M, Lindblad M, Czerkinsky C, Holmgren J.
    APMIS; 2000 Mar 01; 108(3):178-86. PubMed ID: 10752686
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera.
    Xu G, Wang S, Zhuang L, Hackett A, Gu L, Zhang L, Zhang C, Wang H, Huang Z, Lu S.
    Vaccine; 2009 Jun 12; 27(29):3821-30. PubMed ID: 19443090
    [Abstract] [Full Text] [Related]

  • 35. Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans.
    Mestecky J, Michalek SM, Moldoveanu Z, Russell MW.
    Behring Inst Mitt; 1997 Feb 12; (98):33-43. PubMed ID: 9382757
    [Abstract] [Full Text] [Related]

  • 36. Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study.
    Leyten EM, Soonawala D, Schultsz C, Herzog C, Ligthelm RJ, Wijnands S, Visser LG.
    Vaccine; 2005 Oct 17; 23(43):5120-6. PubMed ID: 15982790
    [Abstract] [Full Text] [Related]

  • 37. Mucosal immunity: regulation by helper T cells and a novel method for detection.
    Jackson RJ, Marinaro M, VanCott JL, Yamamoto M, Okahashi N, Fujihashi K, Kiyono H, Chatfield SN, McGhee JR.
    J Biotechnol; 1996 Jan 26; 44(1-3):209-16. PubMed ID: 8717406
    [Abstract] [Full Text] [Related]

  • 38. Bacterial enteric infections and vaccine development.
    Holmgren J, Svennerholm AM.
    Gastroenterol Clin North Am; 1992 Jun 26; 21(2):283-302. PubMed ID: 1512046
    [Abstract] [Full Text] [Related]

  • 39. Combined oral/nasal immunization protects mice from Sendai virus infection.
    Nedrud JG, Liang XP, Hague N, Lamm ME.
    J Immunol; 1987 Nov 15; 139(10):3484-92. PubMed ID: 2824609
    [Abstract] [Full Text] [Related]

  • 40. New vaccines against bacterial enteric infections.
    Holmgren J, Svennerholm AM.
    Scand J Infect Dis Suppl; 1990 Nov 15; 70():149-56. PubMed ID: 2287897
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 54.